Actym Therapeutics

[Actym Therapeutics @ActymT]

Join our colleague Dr. @audyavar on Nov. 4 at #SITC-2023 for our poster presentation. We will feature preclinical data examining the #tumor-specific enrichment & payload delivery of ACTM-838 in multiple tumor models. See you there! Learn more: https://t.co/vpmWwZITaY

[Actym Therapeutics @ActymT]

🗓️ Join us at #SITC2023 on Nov 4!

Our Senior Director of Immunology and Translational Sciences, Dr. @audyavar, will present preclinical data on ACTM-838, our lead asset, in a poster session.

Learn more about the presentation: https://t.co/vpmWwZITaY

See you there, @sitcancer!

[Actym Therapeutics @ActymT]

A warm, official welcome from the Actym team to Dr. Steve Vicik as our new CTO! With 25+ years of experience in #pharma & supply chain development, he will lead our tech strategy & advance our #STACT platform, as it aims to reprogram the #TME. Learn more: https://t.co/Loc17itnon

[Actym Therapeutics @ActymT]

Thank you, @SFBIZronleuty and @SFBusinessTimes, for spotlighting Actym & our #SeriesA extension! And to the Actym team for their hard work, especially as we move into clinical testing. Explore how this #investment fuels the advancement of ACTM-838: https://t.co/kLhc3NtfQA

[Actym Therapeutics @ActymT]

We've secured an extension to our #SeriesA, closing the round with $59.5 million total. This will boost our Phase 1 #clinicaltrial for ACTM-838, aiming to achieve proof of mechanism. Thank you to our #investors for all of your support! Learn more: https://t.co/nl0lG9I1YI

[Actym Therapeutics @ActymT]

Actym's presentation is today! If you're in Orlando, please stop by, we'd love to share our story with you. We are honored to be a part of the AACR Community! #AACR23

[Actym Therapeutics @ActymT]

Our Cancer fighting Rockstars have arrived in Orlando!

[Actym Therapeutics @ActymT]

At Actym Therapeutics, we value giving our employees time off to enjoy the holidays with their families and to recharge for the year ahead.

[Actym Therapeutics @ActymT]

Our colleague @audyavar will present at Informa’s #OncolyticViruses/Non-Viral Gene Delivery Conference today, to be held virtually. She will describe the utility of ACTM-838 to reprogram the tumor microenvironment in solid tumors helping to promote durable anti-tumor immunity.

[Actym Therapeutics @ActymT]

We’re excited to be at the East-West Biopharma Summit sponsored by @Biocentury and to be sharing more about our work to treat #cancer by reprogramming the tumor microenvironment. #BiocenturyEastWest

[Actym Therapeutics @ActymT]

We’re enjoying sharing our strong preclinical data at #SITC22! Please reach out to learn more about ACTM-838’s ability to transform the tumor microenvironment and enable profound immune cell infiltration and activation across several type of immune cells.

[Actym Therapeutics @ActymT]

Akshata Udyavar will be presenting our abstract on ACTM-838 at #SITC22. Stop by Thursday to learn how ACTM-838 comprehensively reprograms the immunosuppressive tumor microenvironment to generate durable anti-tumor immunity, both alone and in combination with anti-PD1 therapy.

[Actym Therapeutics @ActymT]

We’re at #SITC22 to share more about our preclinical work developing ACTM-838, our comprehensive next-gen #immunotherapy that safely generates durable anti-tumor immunity.

[Actym Therapeutics @ActymT]

Really enjoyed discussing our STACT platform technology with the team @WuXi_AppTec for this interview. We can't wait to share more of what we are working on at #SITC22 this week. https://t.co/Ti33Xk9njF

[WuXi AppTec @WuXi_AppTec]

@ActymT is a #BioTech company developing #novel therapies intended to transform the treatment of #cancer. They’ve developed a systemically dosed #therapeutic platform that can overcome solid tumor immune microenvironment, which is hostile to T-cells.
https://t.co/Dhk1ycS1EM

[Actym Therapeutics @ActymT]

Join us at #SITC22 this week! We will be reporting strong preclinical data on our lead candidate ACTM-838, a next-gen #immunotherapy that safely generates durable anti-tumor immunity. https://t.co/TzwmoEVJj5

[Actym Therapeutics @ActymT]

Congratulations to our President and CEO, Christopher Thanos, on being named one of the top 25 CEOs in Biotech by Healthcare Technology Report! We’re grateful for your outstanding leadership, inspiring enthusiasm, and unwavering commitment to patients inflicted with cancer.

[Actym Therapeutics @ActymT]

We're pleased to announce that the USPTO has granted Actym Therapeutics a patent that protects the company's therapeutic technology platform through August of 2039.

https://t.co/Djvjn4wDow

[Actym Therapeutics @ActymT]

We're excited and honored to be featured in a Portfolio Spotlight by Illumina Ventures! #CancelCancer #PatientsFirst https://t.co/pzgBF3rYb7

[Actym Therapeutics @ActymT]

We’re thrilled to announce the closing of a $34 million Series A financing led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Ventures, with participation from Illumina Ventures, Korea Investment Partners (KIP), and JLo Ventures!
https://t.co/ivDTYb6MHb

[Actym Therapeutics @ActymT]

Congratulations to Actym Advisory Board Member, Dr. Gregory Barton, for being named a 2020 American Academy of Microbiology Fellow!
https://t.co/YDIGTmxyxG